PT  - JOURNAL ARTICLE
AU  - Galina Orlova
AU  - Juliya Nikolaeva
AU  - Larisa Kiruchina
AU  - Aleksandra Speranskaya
AU  - Vitaliy Perley
AU  - Aleksey Gichkin
TI  - Follow up 1 year of amiodarone pulmonary effects
DP  - 2011 Sep 01
TA  - European Respiratory Journal
PG  - p3745
VI  - 38
IP  - Suppl 55
4099  - http://erj.ersjournals.com/content/38/Suppl_55/p3745.short
4100  - http://erj.ersjournals.com/content/38/Suppl_55/p3745.full
SO  - Eur Respir J2011 Sep 01; 38
AB  - Amiodaron has numerous side-effects and the pulmonary toxicity (PT) is the most serious.Aim: To analyse the theraputic prognosis of amiodaron-indused PT (AIPT).Methods: 14 AIPT patients (mean age 66,0±1,2 yr), received amiodarone (300-400 mg/day) for 47,6±3,5 months due to cardiac arrhythmia, were investigated. X-ray, computer tomography (CT), complex lung function examination, echodopplercardiography were performed. All patients discontinued the amiodarone and received prednisolone (60-20 mg/day) with gradual tapering up to 5-10 mg/day for 6 months. Lung biopsy was done in 2 cases and confirmed interstitial pulmonary fibrosis.Results: AIPT was diagnosed over 2,7 yr after the clinical manifestation. The onset of AIPT was acute in 3, subacute in 8, insidious in 2 cases. The frequency of CT signs were: interstitial - 1,0, nodule - 0,22 and infiltrative or “ground glass” - 0,78. Restrictive type of functional disorders (0,89), pulmonary hypertension 33,7±1,18 mm Hg and cor pulmonale (0,57) were revealed. In 2 cases it was amiodaron-indused thireoiditis. After 1 yr therapy the improvement of clinical (0,83) and CT (0,83) signs, lung functional tests (DLCO, p<0,05; VC, p<0,005; RV, p<0,001; DLCO, p<0.05) were observed. The rapid decrease of prednisolone dose in 2 cases lead to the clinical and CT deterioration.Conclusion: The corticosteroid treatment of AIPT is of therapeutic value and must be prolonged with carefully tapering to avoid the deterioration.